Captrust Financial Advisors Buys 5,248 Shares of Edwards Lifesciences Co. (NYSE:EW)

Captrust Financial Advisors boosted its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 11.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,703 shares of the medical research company's stock after purchasing an additional 5,248 shares during the quarter. Captrust Financial Advisors' holdings in Edwards Lifesciences were worth $3,680,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter worth about $610,895,000. Jennison Associates LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $555,939,000. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock valued at $314,182,000 after purchasing an additional 3,506,886 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $213,844,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. Evercore ISI dropped their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Barclays boosted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and an average price target of $79.45.

Edwards Lifesciences Trading Down 1.1 %

Shares of EW opened at $73.82 on Friday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm's 50-day moving average price is $71.48 and its 200-day moving average price is $71.50. The firm has a market capitalization of $43.40 billion, a price-to-earnings ratio of 10.59, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.66 EPS. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 5,980 shares of the business's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $74.91, for a total value of $447,961.80. Following the sale, the chief executive officer now directly owns 58,284 shares of the company's stock, valued at approximately $4,366,054.44. The trade was a 9.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company's stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,681 shares of company stock worth $6,492,703. Corporate insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.